Trial · NCT07877675
Fecal Microbiota Transplantation in Females With Anorexia Nervosa
NCT07877675, Not applicable, Not yet recruiting, Andreas Munk Petersen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fecal Microbiota Transplantation in Females With Anorexia Nervosa. Trials, record NCT07877675. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877675
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fecal Microbiota Transplantation in Females With Anorexia Nervosa
- NCT number
- NCT07877675
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Andreas Munk Petersen
- Conditions
- Anorexia Nervosa
- Interventions
- Fecal Microbiota Transplantation Capsule, Placebo Capsule(s)
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Gut Microbiome Composition (T0-T1) | Baseline (T0) - After first 5 weeks (T1) | The primary endpoint is defined as the change in GM composition from baseline (T0) to week 5 (T1), comparing participants randomized to receive FMT during the first treatment period with those randomized to receive placebo during the first treatment period. Microbiome compositions will be assessed using shotgun metagenomic sequencing of stool samples collected at T0 and T1. Global microbiome restructuring will be quantified using pre-specified compositional distance metrics based on centered log-ratio (CLR) transformed abundance data (e.g., Aitchison distance). In addition, the recipient microbiome distance to the assigned donor microbiome will be calculated to quantify movement toward donor composition following treatment. The primary analysis will estimate the difference between-group in microbiome compositional change and donor-recipient distance reduction during the first 5-week treatment period. |
| Secondary | Gut-/appetite-related clinical effects (T0-T1) | Baseline (T0) - After first 5 weeks (T1) | Change from baseline to week 5 in gastrointestinal and appetite-related symptoms, including: Self-reported BMI, gastrointestinal symptom burden, transit time, stool consistency and frequency, appetite and satiety-related biomarkers in serum, and food intake changes. |
| Secondary | Eating-disorder symptom severity (T0-T1) | Baseline (T0) - After first 5 weeks (T1) | Change in eating-disorder symptom severity from baseline compared to placebo using validated eating-disorder questionnaires |
| Secondary | Change in eating-disorder symptom severity from baseline (T0) to the 3-month follow-up (T3) | From baseline (T0) to to the 3-month follow-up (T3) | A secondary longer-term endpoint evaluates change in eating-disorder symptom severity from baseline (T0) to the 3-month follow-up (T3) using validated eating-disorder questionnaires. Because all participants receive FMT during the crossover study design, this outcome is not placebo-controlled and is therefore considered secondary and exploratory. It will determine whether microbiome restructuring, and gut-related clinical changes are associated with changes in eating-disorder symptoms from the participant's own baseline. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers61
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877675
GET https://conductscience.org/api/trials/v1/NCT07877675/papers?page=2